Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2026-03-14 @ 1:08 AM
Study NCT ID:
NCT03010332
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2019-04-08
First Post:
2017-01-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
Sponsor:
Atara Biotherapeutics
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Cytomegalovirus | View |
| None | Cytomegalovirus Viremia | View |
| None | Cytomegalovirus Infection | View |
| None | CMV Infection | View |
| None | Hematopoietic Cell Transplant | View |
| None | Solid Organ Transplant | View |
| None | Human Immunodeficiency Virus | View |
| None | Cytomegalovirus Disease | View |
| None | Hematopoietic Stem Cell Transplant | View |
| None | CMV | View |
| None | CMV syndrome | View |
| None | Cytomegalovirus syndrome | View |
| None | CMV disease | View |
| None | CMV viremia | View |
| None | allogeneic | View |
| None | third-party | View |